Profile
Sector:
HealthcareCountry:
United StatesIPO:
28 September 2000Website:
http://www.durect.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 20:35:41 GMTDividend
Analysts recommendations
Institutional Ownership
DRRX Latest News
Here is how Durect (DRRX) and Elevance Health (ELV) have performed compared to their sector so far this year.
DURECT Corporation's Q1 2024 Earnings Conference Call is scheduled for May 13, 2024 at 4:30 PM ET, with CFO Timothy M. Papp and James E. participating.
Durect (DRRX) reported a quarterly loss of $0.25 per share, which was slightly higher than the Zacks Consensus Estimate of a loss of $0.21. This is an improvement from the loss of $0.52 per share in the same quarter last year.
Durect (DRRX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.46 per share a year ago.
DURECT Corporation (NASDAQ:DRRX ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Conference Call Participants François Brisebois - Oppenheimer Carl Byrnes - Northland Capital Markets Thomas Yip - H.C. Wainwright Operator Good afternoon, everyone, and welcome to the DURECT Corporation Third Quarter Earnings Conference Call.
Durect (NASDAQ: DRRX ) stock is falling hard on Wednesday after the late-stage biopharmaceutical company released results from a Phase 2b clinical trial. This clinical trial covered the efficiency of larsucosterol in treating patients with severe alcohol-associated hepatitis.
For investment ideas that can potentially lead to life-changing gains, few sectors are as viable as biotech stocks to make you rich. Fundamentally, the biotechnology sector offers potential therapeutic innovations that could change paradigms for patient care.
DURECT Corporation (NASDAQ:DRRX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Timothy Papp - CFO & Secretary James Brown - Co-Founder, CEO, President & Director WeiQi Lin - EVP, Research & Development and Principal Scientist Keith Lui - SVP, Business Development, Commercial & Medical Affairs Conference Call Participants Richard Miller - Cantor Fitzgerald Francois Brisebois - Oppenheimer Antonio Arce - H.C. Wainwright & Co. Sean Kim - JonesTrading Operator Greetings, and welcome to the DURECT Corporation Second Quarter Earnings Call.
DURECT Corporation (NASDAQ:DRRX ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Keith Lui - Senior Vice President, Business Development, Commercial, Medical Affairs WeiQi Lin - Executive Vice President, Research and Development, Principal Scientist Norman Sussman - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Ed Arce - H.C. Wainwright Francois Brisebois - Oppenheimer Sean Kim - Jones Trading Operator Greetings and welcome to the DURECT Corporation First Quarter 2023 Earnings Call.
Durect (DRRX) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.50 per share a year ago.
What type of business is DURECT?
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
What sector is DURECT in?
DURECT is in the Healthcare sector
What industry is DURECT in?
DURECT is in the Drug Manufacturers - Specialty & Generic industry
What country is DURECT from?
DURECT is headquartered in United States
When did DURECT go public?
DURECT initial public offering (IPO) was on 28 September 2000
What is DURECT website?
https://www.durect.com
Is DURECT in the S&P 500?
No, DURECT is not included in the S&P 500 index
Is DURECT in the NASDAQ 100?
No, DURECT is not included in the NASDAQ 100 index
Is DURECT in the Dow Jones?
No, DURECT is not included in the Dow Jones index
When does DURECT report earnings?
The next expected earnings date for DURECT is 09 August 2024